Magnetic Field Uniformity Across the GF 9-2 YSO, L1082C Dense Core, and GF 9 Filamentary Dark Cloud

The orientation of the magnetic field (B-field) in the filamentary dark cloud GF 9 was traced from the periphery of the cloud into the L1082C dense core that contains the low-mass, low-luminosity Class 0 young stellar object (YSO) GF 9-2 (IRAS 20503+6006). This was done using SOFIA HAWC+ dust thermal emission polarimetry (TEP) at 216 um in combination with Mimir near-infrared background starlight polarimetry (BSP) conducted at H-band (1.6 um) and K-band (2.2 um). These observations were augmented with published I-band (0.77 um) BSP and Planck 850 um TEP to probe B-field orientations with offset from the YSO in a range spanning 6000 AU to 3 pc. No strong B-field orientation change with offset was found, indicating remarkable uniformity of the B-field from the cloud edge to the YSO environs. This finding disagrees with weak-field models of cloud core and YSO formation. The continuity of inferred B-field orientations for both TEP and BSP probes is strong evidence that both are sampling a common B-field that uniformly threads the cloud, core, and YSO region. Bayesian analysis of Gaia DR2 stars matched to the Mimir BSP stars finds a distance to GF 9 of 270 +/- 10 pc. No strong wavelength dependence of B-field orientation angle was found, contrary to previous claims.Comment: 18 pages, 6 figures ApJ, accepte

Improved Arene Fluorination Methodology for I(III) Salts

The use of low polarity aromatic solvents (benzene or toluene) and/or the removal of inorganic salts results in dramatically improved yields of fluorinated arenes from diaryliodonium salts. This methodology is shown to “scale down” to the conditions used typically for radiotracer synthesis

Paper Session I-C - Technology Advances and Developments in Low Power Gallium Arsenide for Space Applications

The evolution of gallium arsenide (GaAs) technology has developed to the point where it is quite suited for low power operation in space. The preliminary requirements for space-based integrated circuit applications are reviewed, and evidence that a GaAs technology known as complementary heterostructure field effect transistors (CHFETs) has proven to meet the demands of the space environment is presented. Further examples of how the complementary GaAs technology has demonstrated the potential for operation in the Gigahertz frequency range using power supply voltages at or below 2.5 Volts are presented. The analog and digital technological needs for space applications are identified and being met by complementary GaAs technologies when compared to commercial-off-the-shelf (COTS) electronics. Emphasis on the manufacturing costs of low power GaAs technologies when compared to those associated with COTS modified for space applications is addressed. Finally, information by both the Air Force and commercial sector concerning the need for low power GaAs technology insertion into future space-based systems is provided

Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer

Background The toxicity profile of prolonged infusions of paclitaxel in combination with cyclophosphamide in metastat-ic breast cancer has already been defined. The objective of this dose-finding study was to determine the maximum tolerable doses (MTDs) of shorter (three-hour) infusions of paclitaxel in combination with i.v. bolus cyclophosphamide in patients who had previously received a maximum of one chemotherapy for advanced breast carcinoma. The MTD of the same regimen with granulocyte colony-stimulating factor (G-CSF) support was then established. Patients and methods Eighty women with metastatic breast cancer received a total of 352 fully evaluable courses of therapy. The starting doses were paclitaxel 135 mg/m2 and cyclophosphamide 750 mg/m2 given every three weeks. At least three patients were treated at each dose level and if there were dose-limiting toxic effects during the first cycles three additional patients were entered. G-CSF support (5 ug/kg s.c.) was added to the second cycle if specific dose-limiting toxicities had occurred during the first cycle. The MTD was defined as the dose level at which more than two of six patients presented dose-limiting toxicities during the first cycle. Results Febrile neutropenia (n = 4) and severe thrombo-cytopenia (n - 1) defined the MTDs of paclitaxel as 200 mg/m2 and of cyclophosphamide as 2,000 mg/m2 with or without G-CSF in patients with and, respectively, without prior chemotherapy for advanced disease. Non-hematologic toxicity was moderate. Recommended doses were 200 mg/m2 of paclitaxel and 1,750 mg/m2 of cyclophosphamide with or without G-CSF in patients with and, respectively, without prior chemotherapy. The overall response rate was 25% and 50%, respectively, in patients with and without prior chemotherapy for metastatic disease. Complete remissions (9%) were reported only in patients without prior chemotherapy; antitumour activity in women with anthracycline-resistant disease, with an 8% response rate (95% CI: 1%-26%), was poor. Conclusion Paclitaxel at 200 mg/m2 and cyclophosphamide at 1,750 mg/m2 can be safely administered every three weeks to women with advanced breast cancer. The moderate antitumour activity observed with the schedule tested argues against its use as initial therapy for advanced breast cance

Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas

Background: Dose intensive chemotherapy has not been tested prospectively for the treatment of gynecologic sarcomas. We investigated the antitumor activity and toxicity of high-dose ifosfamide and doxorubicin, in the context of a multidisciplinary strategy for the treatment of advanced and metastatic, not pretreated, gynecologic sarcomas. Patients and methods: Thirty-nine patients were enrolled onto a phase I-II multicenter trial of ifosfamide, 10 g/m2 as a continuous infusion over 5 days, plus doxorubicin intravenously, 25 mg/m2/day for 3 days with Mesna and granulocyte-colony-stimulating factor every 21 days. Salvage therapy was allowed after chemotherapy. Results: Among the 37 evaluable patients, the tumor was locally advanced (n = 11), with concomitant distant metastases (n = 5) or with distant metastases only (n = 21). After a median of three (range 1-7) chemotherapy cycles, six patients experienced a complete response and 12 a partial response for an overall response rate of 49% (95% CI 32% to 66%). The response rate was higher in poorly differentiated tumors (62%) compared with moderately well differentiated ones (18%), but was not different according to histology subtypes. Eleven patients had salvage therapy, either immediately following chemotherapy (n = 7) or at time of progression (n = 4). With a median follow-up time of 5 years, the median overall survival was 30.5 months. Hematological toxicity was as expected neutropenia, thrombopenia and anemia ≥grade 3 at 50%, 34% and 33% of cycles respectively. No toxic death occurred. Conclusions: High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas. Its toxicity was manageable in a multicentric setting. The prolonged survival might be due to the multidisciplinary strategy that was possible in one-third of the patient

Extremal Optimization of Graph Partitioning at the Percolation Threshold

The benefits of a recently proposed method to approximate hard optimization problems are demonstrated on the graph partitioning problem. The performance of this new method, called Extremal Optimization, is compared to Simulated Annealing in extensive numerical simulations. While generally a complex (NP-hard) problem, the optimization of the graph partitions is particularly difficult for sparse graphs with average connectivities near the percolation threshold. At this threshold, the relative error of Simulated Annealing for large graphs is found to diverge relative to Extremal Optimization at equalized runtime. On the other hand, Extremal Optimization, based on the extremal dynamics of self-organized critical systems, reproduces known results about optimal partitions at this critical point quite well.Comment: 7 pages, RevTex, 9 ps-figures included, as to appear in Journal of Physics

Ventricular arrhythmia and torsade de pointe: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial

Background: S9788 is a triazineaminopiperidine derivative capable of reversing multidrug resistance (MDR) in vitro. In preclinical models S9788 was several fold more potent MDR inhibitor than verapamil or cyclosporine. At P-glycoprotein (Pgp) blocking concentrations, S9788 appeared to have only very little toxicity. Patients and methods: In a two step phase I trial we treated 39 patients with refractory cancer with S9788 and bolus doxorubicin. The steps differed mainly in the S9788 infusion duration; in the first part 23 patients received the MDR-reversing drug S9788 over 30 minutes, in the second step of the study 16 patients were administered S9788 over 150 minutes. The doses of S9788 were escalated in cohorts of three patients up to a dose level (DL) of 96 mg/m2 on the 30 minutes infusion, and to 144 mg/m2 on the 150 minutes infusion. The pharmaco-kinetics of S9788 were determined. Results: With the 30-minute infusion schedule symptomatic cardiac arrhythmia were found to be dose limiting. In all patients at the highest DL transient cardiac repolarization prolongation with a long QT-interval on ECG was demonstrated. With the 150-minute administration schedule, S9788 could be escalated up to 144 mg/m2 without subjective toxicity. However, transient QT prolongation was present in all patients. A third degree AV-block and a QT increase of about 40% occurred at the highest DL. Asymptomatic torsade de pointe (DL 96 mg/m2) was demonstrated on Holter recording in one patient. Theses repolarization disturbances with QT increase were considered dose limiting toxicity and the trial was closed. No arrhythmia related death was noted. Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively. QTc prolongation duration appeared to be dose-dependent. Conclusions: With the tested infusion schedules, cardiac toxicity, in particular AV-blocks and QT prolongation, leading to ventricular arrhythmia and torsade de pointe, are the dose limiting toxicities of S9788. Our experience together with the observation of asymptomatic torsade de pointe in two other phase I trials of S9788 infused over six hours precluded the further clinical development of S978

Statistical mechanics of a single particle in a multiscale random potential: Parisi landscapes in finite dimensional Euclidean spaces

We construct a N-dimensional Gaussian landscape with multiscale, translation invariant, logarithmic correlations and investigate the statistical mechanics of a single particle in this environment. In the limit of high dimension N>>1 the free energy of the system and overlap function are calculated exactly using the replica trick and Parisi's hierarchical ansatz. In the thermodynamic limit, we recover the most general version of the Derrida's Generalized Random Energy Model (GREM). The low-temperature behaviour depends essentially on the spectrum of length scales involved in the construction of the landscape. If the latter consists of K discrete values, the system is characterized by a K-step Replica Symmetry Breaking solution. We argue that our construction is in fact valid in any finite spatial dimensions $N\ge 1$. We discuss implications of our results for the singularity spectrum describing multifractality of the associated Boltzmann-Gibbs measure. Finally we discuss several generalisations and open problems, the dynamics in such a landscape and the construction of a Generalized Multifractal Random Walk.Comment: 25 pages, published version with a few misprints correcte